Exit, Pursued By a Bear
The buzz of Phoenix '99: In the teeth of their own bear market, device companies are running for any exit they can find because, until recently, the favored exit strategies for small, private medical device companies have been fairly traditional--going public and/or being acquired by a larger firm. But given the dismal performance of small cap device companies recently, the public markets virtually closed down for product companies, leaving only the M&A route. Dealmaking has become more viable as big companies increasingly look to small ones for new products, while small firms gain access to distribution channels, creating a greater co-dependency between the two. In 1999, however, even the M&A door has slammed shut, leaving small companies looking for new financing and business models to deal with the current lack of exit options.
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.